Optimizing the Development of Antipsychotic Drugs (Hardcover)

by Neal R. Cutler (Author), Neil M. Kurz (Author), Michael F. Murphy (Author), Angelico Carta (Author), John J. Sramek (Editor)

Editorial Reviews

Book Description
The interest in developing novel antipsychotics is especially keen at this time and this book presents the latest information in that development. Numerous compounds are in the preclinical and clinical pipeline. The pharmaceutical industry, as well as psychiatrists, clinicians, mental health professionals and anyone else interested in the design and conduct of clinical trials of schizophrenia, are waiting for these research results. Revealing recommendations for developing antipsychotic compounds based on the extensive experience of the authors, this work will provide long-awaited information on a previously unexplored area.

The publisher, John Wiley & Sons
The interest in developing novel anxiolytics is especially keen at this time and this book looks at the latest information in that development. Numerous compounds are in the preclinical pipeline and the pharmaceutical industry, as well as anyone interested in the design and conduct of schizophrenia clinical trials, are waiting for these research results. Revealing recommendations for developing anxiolytic compounds based on the extensive experience of the authors, this work will provide long-awaited information on a so far uncovered new area.

• Hardcover: 204 pages
• Publisher: John Wiley & Sons (January 1997)
• Language: English
• ISBN-10: 0471970115
• ISBN-13: 978-0471970118
• Product Dimensions: 9.3 x 6.2 x 0.7 inches
• Shipping Weight: 15 ounces
• Average Customer Review: No customer reviews yet. Be the first.
• Amazon.com Sales Rank: #4,003,219 in Books (See Bestsellers in Books)
  
  (Publishers and authors: Improve Your Sales)